{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:27:12Z","timestamp":1773271632639,"version":"3.50.1"},"reference-count":32,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Oncolytic adenoviruses represent a promising novel therapeutic option for the treatment of cancer. Despite their demonstrated safety in human clinical trials, the fundamental properties of oncolytic adenovirus biodistribution, spread, viral persistence, and replication in vivo have not been well characterized. The aim of this study was to evaluate the kinetics of viral distribution, spread, replication, and antitumoral efficacy after i.v. administration of a novel oncolytic mutant M1. This mutant consists of the E1A CR2-deleted Adv5 with a fragment of antisense polo-like kinase 1 (plk1) cDNA inserted into the deleted 6.7K\/gp19K region, which combines oncolytic properties with efficient plk1 silencing, as described in our previous reports. In the present study, we established a new human orthotopic gastric carcinoma with a high frequency metastasis mouse model and showed that M1 spread not only in local primary tumors but also in disseminated metastases. M1 could effectively replicate in tumor cells leading to \u201concolysis\u201d and was able to eliminate expression of the targeted gene plk1 in human orthotopic gastric carcinoma model mice. Therefore, i.v. administration of M1 could prolong the survival time of tumor-bearing mice. [Mol Cancer Ther 2008;7(6):1624\u201332]<\/jats:p>","DOI":"10.1158\/1535-7163.mct-07-2134","type":"journal-article","created":{"date-parts":[[2008,6,19]],"date-time":"2008-06-19T18:48:38Z","timestamp":1213901318000},"page":"1624-1632","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration"],"prefix":"10.1158","volume":"7","author":[{"given":"Xiaoyuan","family":"Huang","sequence":"first","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglei","family":"Gao","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Han","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duozhuang","family":"Tang","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xing","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunping","family":"Lu","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Xu","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shixuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding","family":"Ma","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2008,6,19]]},"reference":[{"key":"2022060805041273600_BIB1","doi-asserted-by":"crossref","unstructured":"Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene\u20082000;19:6660\u20139.","DOI":"10.1038\/sj.onc.1204094"},{"key":"2022060805041273600_BIB2","doi-asserted-by":"crossref","unstructured":"Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res\u20082000;6:3395\u20139.","DOI":"10.21236\/ADA395216"},{"key":"2022060805041273600_BIB3","doi-asserted-by":"crossref","unstructured":"Aghi M, Martuza RL. Oncolytic viral therapies\u2014the clinical experience. Oncogene\u20082005;24:7802\u201316.","DOI":"10.1038\/sj.onc.1209037"},{"key":"2022060805041273600_BIB4","unstructured":"Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res\u20082002;62:6070\u20139."},{"key":"2022060805041273600_BIB5","doi-asserted-by":"crossref","unstructured":"Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol\u20082001;19:289\u201398.","DOI":"10.1200\/JCO.2001.19.2.289"},{"key":"2022060805041273600_BIB6","doi-asserted-by":"crossref","unstructured":"Sauthoff H, Hu J, Maca C, et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther\u20082003;14:425\u201333.","DOI":"10.1089\/104303403321467199"},{"key":"2022060805041273600_BIB7","doi-asserted-by":"crossref","unstructured":"Jogler C, Hoffmann D, Theegarten D, Grunwald T, Uberla K, Wildner O. Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J Virol\u20082006;80:3549\u201358.","DOI":"10.1128\/JVI.80.7.3549-3558.2006"},{"key":"2022060805041273600_BIB8","doi-asserted-by":"crossref","unstructured":"Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med\u20082001;7:781\u20137.","DOI":"10.1038\/89901"},{"key":"2022060805041273600_BIB9","doi-asserted-by":"crossref","unstructured":"Chiocca EA. Oncolytic viruses. Nat Rev Cancer\u20082002;2:938\u201350.","DOI":"10.1038\/nrc948"},{"key":"2022060805041273600_BIB10","doi-asserted-by":"crossref","unstructured":"Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther\u20082005;12:141\u201361.","DOI":"10.1038\/sj.cgt.7700771"},{"key":"2022060805041273600_BIB11","doi-asserted-by":"crossref","unstructured":"Le LP, Le HN, Dmitriev IP, et al. Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst\u20082006;98:203\u201314.","DOI":"10.1093\/jnci\/djj022"},{"key":"2022060805041273600_BIB12","doi-asserted-by":"crossref","unstructured":"Zhou J, Gao Q, Chen G, et al. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin Cancer Res\u20082005;11:8431\u201340.","DOI":"10.1158\/1078-0432.CCR-05-1085"},{"key":"2022060805041273600_BIB13","doi-asserted-by":"crossref","unstructured":"Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol\u20081995;3:207\u201320.","DOI":"10.1007\/BF02789331"},{"key":"2022060805041273600_BIB14","doi-asserted-by":"crossref","unstructured":"Motoyama T, Hojo H, Watanabe H. Comparison of seven cell lines derived from human gastric carcinomas. Acta Pathol Jpn\u20081986;36:65\u201383.","DOI":"10.1111\/j.1440-1827.1986.tb01461.x"},{"key":"2022060805041273600_BIB15","doi-asserted-by":"crossref","unstructured":"Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP, Lieber A. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther\u20082005;16:664\u201377.","DOI":"10.1089\/hum.2005.16.664"},{"key":"2022060805041273600_BIB16","doi-asserted-by":"crossref","unstructured":"Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood\u20082007;109:2832\u20139.","DOI":"10.1182\/blood-2006-06-032524"},{"key":"2022060805041273600_BIB17","doi-asserted-by":"crossref","unstructured":"Hawkins LK, Johnson L, Bauzon M, et al. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K\/gp19 K region. Gene Ther\u20082001;8:1123\u201331.","DOI":"10.1038\/sj.gt.3301507"},{"key":"2022060805041273600_BIB18","doi-asserted-by":"crossref","unstructured":"O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell\u20082005;8:61\u201374.","DOI":"10.1016\/j.ccr.2005.06.009"},{"key":"2022060805041273600_BIB19","doi-asserted-by":"crossref","unstructured":"Thorne SH, Bartlett DL, Kirn DH. The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr Gene Ther\u20082005;5:429\u201343.","DOI":"10.2174\/1566523054546215"},{"key":"2022060805041273600_BIB20","unstructured":"Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res\u20082000;60:6359\u201366."},{"key":"2022060805041273600_BIB21","doi-asserted-by":"crossref","unstructured":"Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent\/refractory epithelial ovarian cancer. J Clin Oncol\u20082002;20:1562\u20139.","DOI":"10.1200\/JCO.20.6.1562"},{"key":"2022060805041273600_BIB22","doi-asserted-by":"crossref","unstructured":"Tsai V, Johnson DE, Rahman A, et al. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res\u20082004;10:7199\u2013206.","DOI":"10.1158\/1078-0432.CCR-04-0765"},{"key":"2022060805041273600_BIB23","doi-asserted-by":"crossref","unstructured":"Andarini S, Kikuchi T, Nukiwa M, et al. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res\u20082004;64:3281\u20137.","DOI":"10.1158\/0008-5472.CAN-03-3911"},{"key":"2022060805041273600_BIB24","doi-asserted-by":"crossref","unstructured":"Ryan PC, Jakubczak JL, Stewart DA, et al. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther\u20082004;11:555\u201369.","DOI":"10.1038\/sj.cgt.7700735"},{"key":"2022060805041273600_BIB25","unstructured":"Wodarz D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res\u20082001;61:3501\u20137."},{"key":"2022060805041273600_BIB26","doi-asserted-by":"crossref","unstructured":"Kruyt FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther\u20082002;13:485\u201395.","DOI":"10.1089\/10430340252809784"},{"key":"2022060805041273600_BIB27","doi-asserted-by":"crossref","unstructured":"Ganly I, Kim YT, Hann B, Balmain A, Brown R. Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis. Gene Ther\u20082001;8:369\u201375.","DOI":"10.1038\/sj.gt.3301402"},{"key":"2022060805041273600_BIB28","doi-asserted-by":"crossref","unstructured":"Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med\u20082000;6:879\u201385.","DOI":"10.1038\/78638"},{"key":"2022060805041273600_BIB29","doi-asserted-by":"crossref","unstructured":"Min Y, Adachi Y, Yamamoto H, et al. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut\u20082005;54:591\u2013600.","DOI":"10.1136\/gut.2004.048926"},{"key":"2022060805041273600_BIB30","doi-asserted-by":"crossref","unstructured":"Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res\u20082007;13:341\u20139.","DOI":"10.1158\/1078-0432.CCR-06-1838"},{"key":"2022060805041273600_BIB31","doi-asserted-by":"crossref","unstructured":"White E. Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene\u20082001;20:7836\u201346.","DOI":"10.1038\/sj.onc.1204861"},{"key":"2022060805041273600_BIB32","unstructured":"Stiewe T, Parssanedjad K, Esche H, Opalka B, Putzer BM. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents. Cancer Res\u20082000;60:3957\u201364."}],"container-title":["Molecular Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/7\/6\/1624\/1880905\/1624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/7\/6\/1624\/1880905\/1624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T07:05:17Z","timestamp":1654671917000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/mct\/article\/7\/6\/1624\/235617\/Biodistribution-and-kinetics-of-the-novel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,6,19]]},"published-print":{"date-parts":[[2008,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1535-7163.mct-07-2134","relation":{},"ISSN":["1535-7163","1538-8514"],"issn-type":[{"value":"1535-7163","type":"print"},{"value":"1538-8514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,1]]}}}